Document Detail


Median nerve conduction velocity and central conduction time measured with somatosensory evoked potentials in thyroxine-treated infants with Down syndrome.
MedLine Citation:
PMID:  16923926     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of this study was to determine whether thyroxine treatment would improve nerve conduction in infants with Down syndrome. METHODS: A single-center, nationwide, randomized, double-blind, clinical trial was performed. Neonates with Down syndrome were assigned randomly to thyroxine (N = 99) or placebo (N = 97) treatment for 2 years. Daily thyroxine doses were adjusted regularly to maintain plasma thyrotropin levels in the normal range and free thyroxine concentrations in the high-normal range. The outcome measures were nerve conduction velocity and central conduction time, determined through median nerve somatosensory evoked potential recording, at the age of 24 months. RESULTS: At the age of 24 months, somatosensory evoked potential recordings for 81 thyroxine-treated and 84 placebo-treated infants were available for analysis. Nerve conduction velocity and central conduction time did not differ significantly between the 2 treatment groups (nerve conduction velocity: thyroxine: 51.0 m/second; placebo: 50.1 m/second; difference: 0.9 m/second; central conduction time: thyroxine: 8.83 milliseconds; placebo: 8.73 milliseconds; difference: 0.1 milliseconds). CONCLUSIONS: Postnatal thyroxine treatment of infants with Down syndrome did not alter somatosensory evoked potential-measured peripheral or central nerve conduction significantly. The absence of favorable effects suggests that pathologic mechanisms other than mild postnatal hypothyroidism underlie the impaired nerve conduction. The absence of adverse effects suggests that longstanding plasma free thyroxine concentrations in the high-normal range are not harmful to nerve maturation.
Authors:
A S Paul van Trotsenburg; Bert J Smit; Johannes H T M Koelman; Marijke Dekker-van der Sloot; Jeannette C D Ridder; Jan G P Tijssen; Jan J M de Vijlder; Thomas Vulsma
Related Documents :
9512206 - Thyroid hormone concentrations in preterm infants born to pre-eclamptic women with plac...
12841536 - Thyroid function in breast-fed infants is not affected by methimazole-induced maternal ...
17917306 - Successful intrauterine therapy for fetal goitrous hypothyroidism during late gestation.
8636826 - Prediction of neonatal hyperthyroidism in infants born to mothers with graves disease.
10550966 - Pediatric cardiac auscultation.
21729336 - Colic in infants.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-08-21
Journal Detail:
Title:  Pediatrics     Volume:  118     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-04     Completed Date:  2006-09-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e825-32     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatric Endocrinology, Emma Children's Hospital Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. a.s.vantrotsenburg@amc.uva.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Double-Blind Method
Down Syndrome / complications*
Evoked Potentials, Somatosensory*
Female
Humans
Hypothyroidism / complications,  drug therapy*,  etiology*
Infant, Newborn
Male
Median Nerve / physiology*
Neural Conduction
Thyroxine / therapeutic use*
Chemical
Reg. No./Substance:
7488-70-2/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravenous injection of pharmaceutical tablets presenting as multiple pulmonary nodules and declini...
Next Document:  Comparing patients seen in pediatric resident continuity clinics and national ambulatory medical car...